These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 31417938)

  • 1. Update on pharmacotherapy for ocular surface squamous neoplasia.
    Al Bayyat G; Arreaza-Kaufman D; Venkateswaran N; Galor A; Karp CL
    Eye Vis (Lond); 2019; 6():24. PubMed ID: 31417938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical treatment for ocular surface squamous neoplasia.
    Monroy D; Serrano A; Galor A; Karp CL
    Eye (Lond); 2023 Apr; 37(5):885-893. PubMed ID: 36754986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and Medical Management of Ocular Surface Squamous Neoplasia.
    Sayed-Ahmed IO; Palioura S; Galor A; Karp CL
    Expert Rev Ophthalmol; 2017; 12(1):11-19. PubMed ID: 28184236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of topical interferon alpha-2b in 'mitomycin-C-resistant' ocular surface squamous neoplasia: our preliminary findings.
    Singh M; Gautam N; Kaur M
    Int Ophthalmol; 2019 Feb; 39(2):295-301. PubMed ID: 29362973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the Management of Ocular Surface Squamous Neoplasia.
    Patel U; Karp CL; Dubovy SR
    Curr Ophthalmol Rep; 2021 Mar; 9(1):7-15. PubMed ID: 34804642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitomycin C or interferon as adjuvant therapy to surgery for ocular surface squamous neoplasia: comparative study.
    Blasi MA; Maceroni M; Sammarco MG; Pagliara MM
    Eur J Ophthalmol; 2018 Mar; 28(2):204-209. PubMed ID: 28967069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical chemotherapy for ocular surface squamous neoplasia.
    Nanji AA; Sayyad FE; Karp CL
    Curr Opin Ophthalmol; 2013 Jul; 24(4):336-42. PubMed ID: 23680759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon Alfa 2b for Ocular Surface Squamous Neoplasia: Factors Influencing the Treatment Response.
    Kaliki S; Bejjanki KM; Desai A; Mohamed A
    Semin Ophthalmol; 2019; 34(7-8):465-472. PubMed ID: 31370766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute anterior uveitis after topical interferon for conjunctival intraepithelial neoplasia (CIN).
    Naravane AV; Weber J; Barucha G; Hou JH
    GMS Ophthalmol Cases; 2021; 11():Doc11. PubMed ID: 34540523
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunosuppression as a Possible Risk Factor for Interferon Nonresponse in Ocular Surface Squamous Neoplasia.
    Ashkenazy N; Karp CL; Wang G; Acosta CM; Galor A
    Cornea; 2017 Apr; 36(4):506-510. PubMed ID: 28129301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes after adjunctive topical 5-flurouracil or mitomycin C for the treatment of surgically excised, localized ocular surface squamous neoplasia.
    Bahrami B; Greenwell T; Muecke JS
    Clin Exp Ophthalmol; 2014; 42(4):317-22. PubMed ID: 23927413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Management of Ocular Surface Squamous Neoplasia (OSSN).
    Yeoh CHY; Lee JJR; Lim BXH; Sundar G; Mehta JS; Chan ASY; Lim DKA; Watson SL; Honavar SG; Manotosh R; Lim CHL
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical interferon alpha-2b for treatment of noninvasive ocular surface squamous neoplasia with 360° limbal involvement.
    Zarei-Ghanavati S; Alizadeh R; Deng SX
    J Ophthalmic Vis Res; 2014; 9(4):423-6. PubMed ID: 25709765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Topical 5-Fluorouracil and Interferon Alfa-2b as Primary Treatment Modalities for Ocular Surface Squamous Neoplasia.
    Venkateswaran N; Mercado C; Galor A; Karp CL
    Am J Ophthalmol; 2019 Mar; 199():216-222. PubMed ID: 30471241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical pharmacotherapy for ocular surface squamous neoplasia: systematic review and meta-analysis.
    Kozma K; Dömötör ZR; Csutak A; Szabó L; Hegyi P; Erőss B; Helyes Z; Molnár Z; Dembrovszky F; Szalai E
    Sci Rep; 2022 Aug; 12(1):14221. PubMed ID: 35987957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel ocular immunotherapy induces tumor regression in an equine model of ocular surface squamous neoplasia.
    Wotman KL; Chow L; Martabano B; Pezzanite LM; Dow S
    Cancer Immunol Immunother; 2023 May; 72(5):1185-1198. PubMed ID: 36367558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and Severity of Ocular Surface Neoplasia in African Nations and Need for Early Interventions.
    Reynolds JW; Pfeiffer ML; Ozgur O; Esmaeli B
    J Ophthalmic Vis Res; 2016; 11(4):415-421. PubMed ID: 27994810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of diffuse ocular surface squamous neoplasia: efficacy and complications of topical chemotherapy.
    Rudkin AK; Dempster L; Muecke JS
    Clin Exp Ophthalmol; 2015; 43(1):20-5. PubMed ID: 24995542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular surface squamous neoplasia: a standard of care survey.
    Stone DU; Butt AL; Chodosh J
    Cornea; 2005 Apr; 24(3):297-300. PubMed ID: 15778602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Pegylated Interferon and Mitomycin C on Ocular Surface Squamous Neoplasia in Xeroderma Pigmentosum: A Case Series.
    Dirar QS; Musalem HM; Al-Hazzaa SAF; Al Zoba AA; Almalki AA
    Am J Case Rep; 2020 Apr; 21():e921301. PubMed ID: 32251268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.